Scroll to top

Regulatory

CLINUVEL
Posted by CLINUVEL
March 24, 2021

SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)

CLINUVEL today announced that it has reached agreement with clinical and academic...

Read More
CLINUVEL
Posted by CLINUVEL
February 11, 2021

SCENESSE® Granted Market Access In Israel

CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Media Release – CLINUVEL to Trial Innovative Drug in Stroke

The drug afamelanotide will be used for the first time in patients...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Media Release – TGA approves Australian drug to protect patients from light and sun

New Australian-developed drug approved by TGA for metabolic disorder erythropoietic protoporphyria (EPP)...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Australian TGA approves SCENESSE®

Executive summary SCENESSE® approved by Australian TGA under Priority Review First approved...

Read More
CLINUVEL
Posted by CLINUVEL
September 14, 2020

Media Release - First patient dosed in SCENESSE® DNA Repair Program

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

Media Release (ASX) - CLINUVEL progresses innovative DNA Repair Program

Drug tested to protect skin and regenerate DNA, firstly in XP patients...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

Media Release – New drug to repair damaged skin and reduce skin cancer risk

Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with...

Read More
CLINUVEL
Posted by CLINUVEL
September 10, 2020

SCENESSE® in DNA Repair

CLINUVEL to confirm cellular DNA repair in rare disease xeroderma pigmentosum (XP)...

Read More
CLINUVEL
Posted by CLINUVEL
July 13, 2020

Media Release - Second Afamelanotide Formulation

PRÉNUMBRA®- CLINUVEL’S SECOND AFAMELANOTIDE FORMULATION Drug to be evaluated in patients with...

Read More
We use cookies to give you the best experience.